期刊文献+

TGF-β ⅡR单链抗体/轻链恒定区/鱼精蛋白截短体融合蛋白携带miR-29b抗肝纤维化的研究

Effect of miR-29b transfected by anti-TGF-β ⅡR ScFv/Ck/tP fusion protein on liver fibrosis
原文传递
导出
摘要 目的观察TGF-β ⅡR单链抗体/轻链恒定区/鱼精蛋白截短体融合蛋白(简称新型载体)携带miR-29b对体外培养肝星状细胞(HSC)的转染效率和治疗效果,为今后肝纤维化基因治疗提供新裁体。方法脂质体、新型载体和慢病毒携带miR-29b治疗体外培养的HSC,荧光显微镜和流式细胞术观察转染效率,实时荧光定量RT-PCR和WesternBlot技术分析collagen αl(I)mRNA和蛋白表达水平。结果与对照组比较,慢病毒组的转染效率最高,为70%;其次为新型载体组,为58%;最后为脂质体组,为29%。各载体组collagen αl(I)mRNA表现出不同的下降,与对照组比较,慢病毒组下降70%(t=6.316,P〈0.01),新型载体组为50%(t=4.082,P〈0.01),脂质体组为38%(t=3.014,P〈0.05)。各载体组collagen αl(I)蛋白也表现出不同的下降,慢病毒组下降为59%(t=4.209,P〈0.01);新型载体组为41%(t=4.033,P〈0.01;);脂质体组为27%(t=2.842,P〈0.05)。结论笔者构建的新型载体具有较高的转染效率,并且携带miR-29b具有较好的抗肝纤维化效果。 Objective To observe the transfection efficiency and anti-fibrotic effect of miR-29b transfected by anti-TGF-β ⅡR R ScFv/Ck/tP fusion protein (new vector) in hepatic stellate cell (HSC), and to provide a new vector in gene therapy for liver fibrosis. Methods The liposome vector, new vector, and lentiviral vector were used as transfection reagents to transfect miR-29b into HSC. Transfection efficiency was observed under fluorescence microscope and flow cytometry. Collagen cd (I) mRNA and protein expres- sion in different groups were analyzed by real-time RT-PCR and Western Blot, respectively. Results Com- pared to the control, transfection efficiencies in lentiviral vector, new vector, and liposome vector groups were about 70%, 58% , and 29% , respectively. Collagen α1 (I) mRNA expression in lentiviral vector, new vector, and hposome vector groups was decreased by about 70%, 50%, and 38%, respectively ( ( t =6.316, P 〈0. 01;t =4.082, P 〈0.01;t =3.014, P 〈0.05). Collagen αl(I) protein expression in lentiviral vector, new vector, and liposome vector groups was decreased by about 59%, 41% , and 27% , respectively (t =4.209, P 〈0.01; t =4.033, P 〈0.01; t =2.842, P 〈0.05). Conclusions The new vector constructed by us has a high transfection efficiency. MiR-29b transfected by the new vector has a good anti-liver fibrosis effect.
出处 《中国医师杂志》 CAS 2012年第10期1331-1334,共4页 Journal of Chinese Physician
基金 国家自然科学基金项目(81000176,81100292) 浙江省自然科学基金项目(Y2110634,Y2090326) 王宝恩肝纤维化研究基金项目(20100002) 温州市科技局项目(Y20110033)
关键词 鱼精蛋白类 遗传学 重组融合蛋白质类 遗传学 微RNAS 肝硬化 Protamines/genetics Recombinant fusion Proteins/genetics MicroRNAs Liver cir rhosis
  • 相关文献

参考文献12

  • 1Iwaisako K, Brenner DA, Kisseleva T. What new in liver fibro- sis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol,2012,27 Suppl 2:65-68.
  • 2Kisseleva T, Brenner DA. Anti-fibrogenic strategies and the regres- sion of fibrosis. Best Pract Res Clin Gastroenterol,2011,25 (2): 305-317.
  • 3付荣泉,谭德明,丁继光,吴金国,洪亮,孙庆丰.TGFβRⅡ-siRNA表达质粒构建及干扰效应鉴定[J].中国医师杂志,2010,12(4):444-447. 被引量:2
  • 4de Marco A. Biotechnological applications of recombinant single- domain antibody fragments. Microb Cell Fact,2011,10:44.
  • 5Sakaida I. Autologous bone marrow cell infusion therapy for liver cirrhgsis-now and future. Rinsho Byori, 2011,59 ( 12 ) : 1092- 1098.
  • 6Povero D, Busletta C, Novo E, et al. Liver fibrosis : a dynamic and potentially reversible process. Histol Histopathol, 2010,25 ( 8 ) : 1075-1091.
  • 7俞富军,董培红,范栩妃,陈永平,李骥.脂联素抑制大鼠肝星状细胞株HSC-T6的Ⅲ型前胶原和透明质酸的表达[J].中国医师杂志,2011,13(2):150-153. 被引量:2
  • 8Sekiya Y, Ogawa T, Yoshizato K, et al. Suppression of hepatic stellate cell activation by microRNA-29b. Biochem Biophys Res Commun,2011,412( 1 ) :74-79.
  • 9Roderburg C, Urban GW, Bettermann K,et al. Micro-RNA profi- ling reveals a role for miR-29 in human and murine liver fibrosis. Heoatoloav .2011.53 ( 1 ), 209-218.
  • 10Chen H, Zhou Y, Chen KQ,et al. Anti-fibrotic effects via regula- tion of transcription factor Spl on hepatic stellate cells. Cell Phys- iol Biochem,2012,29(1-2) :51-60.

二级参考文献19

  • 1Schuppan D,Popov Y.Rationale and targets for antifibrotic therapies.Gastroenterol Clin Biol,2009,33(10):949-957.
  • 2Balsano C,Alisi A,Nobili V.Liver fibrosis and therapeutic strategies:the goal for improving metabolism.Curr Drug Targets,2009,10(6):505-512.
  • 3Goyal BR,Patel MM,Soni MK,et al.Therapeutic opportunities of small Interfering RNA.Fundam Clin Pharmacol,2009,23 (4):367-386.
  • 4Mauviel A.Transforming growth factor-beta:a key mediator of fibrosis.Methods Mol Med,2005,117:69-80.
  • 5Sun BK,Tsao H.Small RNAs in development and disease.J Am Acad Dermatol,2008,59 (5):725-737.
  • 6Hu PF,Xie WF.Targeted RNA interference for hepatic fibrosis.Expert Opin Biol Ther,2009,9(10):1305-1312.
  • 7Ma B,Hernandez N.Redundant cooperative interactions for assembly of a human U6 transcription initiation complex.Mol Cell Biol,2002,22:8067-8078.
  • 8Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol, 2008,214(2) :199-210.
  • 9Nam JS, Park JS, Cho MH, et al. The association between pulse wave velocity and metabolic syndrome and adiponectin in patients with impaired fasting glucose: cardiovascular risks and adiponectin in IFG. Diabetes Res Clin Pract ,2009,84 (2) :145-151.
  • 10Savvidou S, Hytiroglou P, Orfanou-Koumerkeridou H, et al. Low se- rum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD. J Clin Gastroenterol,2009,43 (8) :765- 772.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部